Lung Cancer Clinical Trial
Official title:
A Phase II Trial of Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With EGFR Activating Mutations
Advanced stage lung cancer is generally treated with anti-cancer medication called
chemotherapy. Most lung cancer is caused by cigarette smoking. However, some lung cancers
develop in people who never smoked or who only smoked for a short period of time. This type
of lung cancer may respond to a medication called erlotinib (Tarceva). Erlotinib is an
anticancer pill that is approved by the Food and Drug Administration (FDA) for use in
patients with advanced lung cancer. Unfortunately, erlotinib does not work for all patients
or only works for a period of time. The doctors are trying to find ways to improve the
effect of erlotinib by combining it with another anti-cancer medication.
Ascenta Therapeutics, Inc. has developed a drug called AT-101 as a potential treatment for
cancer. AT-101 is an investigational drug. That means that AT-101 is not approved by the
United States Food and Drug Administration (FDA) for general use. The FDA does permit its
use in studies like this one to determine whether it is safe and effective.
This is the first study to examine the effects of AT-101 and erlotinib. It is hoped that by
combining AT-101 with erlotinib, AT-101 may help erlotinib work better to shrink lung
cancer. Studies that have been performed in the laboratory suggest that AT-101 in
combination with erlotinib may be more effective at shrinking tumors than erlotinib alone.
Status | Terminated |
Enrollment | 6 |
Est. completion date | May 2010 |
Est. primary completion date | May 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Ability to understand and the willingness to sign a written informed consent form; the consent form must be signed by the patient prior to any study-specific procedures. - Patients age = 18 years with histologically confirmed wet Stage IIIB (with malignant pleural effusion) or Stage IV non-small cell lung cancer (metastatic or recurrent). - Pathologic confirmation of non-small cell lung cancer at Memorial Sloan-Kettering Cancer Center. - Presence of exon 19 or exon 21 EGFR activating mutation. - No prior EGFR tyrosine kinase therapy. - No prior systemic therapy for advanced NSCLC (Stage IIIB with malignant effusion or Stage IV) - Karnofsky performance status > or = to 70% OR ECOG performance status = 2. - Measurable disease defined as greater than or equal to one known/suspected malignant lesion > or = to 1 cm measurable in two dimensions. - Adequate hematologic, renal, and/or hepatic function: WBC > or = to 3,000/ul, hemoglobin > or = to 9.0 g/dl, platelet count > or = to 100,000/ul, total bilirubin = 1.5 X UNL, AST = 2.5 X UNL, and serum creatinine within 1.5 x the upper limit of normal (<1.95 at MSKCC) or calculated creatinine clearance > or = to 60 ml/min. - Able to swallow and retain oral medication. - Willingness and ability to comply with study procedures and follow-up examination. - Four weeks since any major surgery, completion of radiation, or completion of all prior chemotherapy. - Acute toxicities of any prior therapy must have resolved to < Grade 1 or baseline prior to starting study therapy. - Effective contraception. Exclusion Criteria: - Prior treatment with gefitinib, erlotinib, or other EGFR tyrosine kinase inhibitor therapy. - Concurrent cytotoxic or biological therapy. - Known KRAS mutation. - History within the past 6 months of myocardial infarction, cardiac stent placement, or intermittent ischemia with troponin leak. - Active secondary malignancy or history of other malignancy within the last 3 years except non-melanoma skin cancer and in-situ carcinoma of the cervix. - Active, serious comorbid medical conditions including severe infection, malnutrition, unstable angina, congestive heart failure (New York Heart Association Class III or IV), pulmonary fibrosis, or condition that would be felt by treating physician to preclude safe participation in the clinical trial. - Patients with malabsorption syndrome or diseases significantly affecting the gastrointestinal tract including prior gastric resection or small bowel resection, inflammatory bowel disease, or partial or complete small bowel obstruction. - Unstable brain or leptomeningeal metastases including patients who continue to require glucocorticoids for brain or leptomeningeal metastases. - Women who are pregnant or breast-feeding. - Inability/unwillingness to comply with protocol treatment or follow-up. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Memorial Sloan Kettering Cancer Center | Ascenta Therapeutics |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Radiographic Objective Response Rate | (CR+PR, by WHO Criteria for Standard Bidimensional Tumor Measurement) After One 21-day Cycle of Combination Therapy With Erlotinib and AT-101 | 21 days after cycle one | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|